Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Misses on EPS, Stock Up 1.78%

Arrowhead Pharmaceuticals reported an EPS of $0.24, which was below expectations, resulting in a surprise of nearly 35%. Despite this miss, the stock rose by 1.78%, indicating that investors may have reacted positively to other aspects of the company's performance or outlook not detailed in the earnings report.